These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 15304033)

  • 1. Challenges in the prevention of venous thromboembolism in the elderly.
    Di Minno G; Tufano A
    J Thromb Haemost; 2004 Aug; 2(8):1292-8. PubMed ID: 15304033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV; Bounameaux H
    Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.
    Tran AH; Lee G
    Ann Pharmacother; 2003 Nov; 37(11):1632-43. PubMed ID: 14565815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis.
    Bauer KA
    Am J Orthop (Belle Mead NJ); 2002 Nov; 31(11 Suppl):4-10. PubMed ID: 12463577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study.
    Colwell CW; Berkowitz SD; Davidson BL; Lotke PA; Ginsberg JS; Lieberman JR; Neubauer J; McElhattan JL; Peters GR; Francis CW
    J Thromb Haemost; 2003 Oct; 1(10):2119-30. PubMed ID: 14521593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism.
    Bauer KA; Eriksson BI; Lassen MR; Turpie AG
    Curr Opin Pulm Med; 2002 Sep; 8(5):398-404. PubMed ID: 12172443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
    Evans HC; Perry CM; Faulds D
    Drugs; 2004; 64(6):649-78. PubMed ID: 15018597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.
    Turpie AG
    Surg Technol Int; 2004; 13():261-7. PubMed ID: 15744699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery.
    Andersen JC
    Semin Thromb Hemost; 2004 Dec; 30(6):609-18. PubMed ID: 15630666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systematic review.
    Nijkeuter M; Huisman MV
    Curr Opin Pulm Med; 2004 Sep; 10(5):338-44. PubMed ID: 15316429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with ximelagatran in orthopaedic surgery.
    Eriksson B
    Drugs; 2004; 64 Suppl 1():27-35. PubMed ID: 15586625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fondaparinux: a new antithrombotic agent.
    Cheng JW
    Clin Ther; 2002 Nov; 24(11):1757-69; discussion 1719. PubMed ID: 12501872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
    Schulman S; Wåhlander K; Lundström T; Clason SB; Eriksson H;
    N Engl J Med; 2003 Oct; 349(18):1713-21. PubMed ID: 14585939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical potential of oral direct thrombin inhibitors in the prevention and treatment of venous thromboembolism.
    Agnelli G
    Drugs; 2004; 64 Suppl 1():47-52. PubMed ID: 15586627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
    Francis CW; Berkowitz SD; Comp PC; Lieberman JR; Ginsberg JS; Paiement G; Peters GR; Roth AW; McElhattan J; Colwell CW;
    N Engl J Med; 2003 Oct; 349(18):1703-12. PubMed ID: 14585938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
    Eriksson BI; Agnelli G; Cohen AT; Dahl OE; Lassen MR; Mouret P; Rosencher N; Kälebo P; Panfilov S; Eskilson C; Andersson M; Freij A;
    J Thromb Haemost; 2003 Dec; 1(12):2490-6. PubMed ID: 14675083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy.
    Turpie AG
    Expert Opin Pharmacother; 2004 Jun; 5(6):1373-84. PubMed ID: 15163281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective factor Xa inhibition improves efficacy of venous thromboembolism prophylaxis in orthopedic surgery.
    Comp PC
    Pharmacotherapy; 2003 Jun; 23(6):772-87. PubMed ID: 12820819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.